Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

RECOVERY Collaborative Group None. et al, (2022)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), The Lancet. Respiratory medicine, 9, 1419 - 1426

The impact of atrial fibrillation and stroke risk factors on left atrial blood flow characteristics.

Spartera M. et al, (2021), Eur Heart J Cardiovasc Imaging

The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19.

Pessoa-Amorim G. and Mafham MM., (2021), Cardiovasc Res, 117, e110 - e113

Making trials part of good clinical care: lessons from the RECOVERY trial.

Pessoa-Amorim G. et al, (2021), Future Healthc J, 8, e243 - e250

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group None. et al, (2021)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group None. et al, (2021)

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 1637 - 1645

Left atrial 4D flow cardiovascular magnetic resonance: a reproducibility study in sinus rhythm and atrial fibrillation.

Spartera M. et al, (2021), J Cardiovasc Magn Reson, 23

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The RECOVERY Collaborative Group None. et al, (2021)

Left ventricular reverse remodeling and function by strain analysis in aortic stenosis: A CMR analysis of the EPICHEART study.

Azevedo D. et al, (2021), Rev Port Cardiol (Engl Ed), 40, 153 - 164

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group None. et al, (2021)

Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby P. et al, (2020)

Influence of EPICardial adipose tissue in HEART diseases (EPICHEART) study: Protocol for a translational study in coronary atherosclerosis.

Mancio J. et al, (2020), Rev Port Cardiol (Engl Ed), 39, 625 - 633

Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European Society of Cardiology.

Pessoa-Amorim G. et al, (2020), Eur Heart J Qual Care Clin Outcomes, 6, 210 - 216

Epicardial adipose tissue volume and annexin A2/fetuin-A signalling are linked to coronary calcification in advanced coronary artery disease: Computed tomography and proteomic biomarkers from the EPICHEART study.

Mancio J. et al, (2020), Atherosclerosis, 292, 75 - 83

Impaired Left Atrial Strain as a Predictor of New-onset Atrial Fibrillation After Aortic Valve Replacement Independently of Left Atrial Size.

Pessoa-Amorim G. et al, (2018), Rev Esp Cardiol (Engl Ed), 71, 466 - 476

Load More

Include forthcoming?